MX2018013762A - Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso. - Google Patents

Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso.

Info

Publication number
MX2018013762A
MX2018013762A MX2018013762A MX2018013762A MX2018013762A MX 2018013762 A MX2018013762 A MX 2018013762A MX 2018013762 A MX2018013762 A MX 2018013762A MX 2018013762 A MX2018013762 A MX 2018013762A MX 2018013762 A MX2018013762 A MX 2018013762A
Authority
MX
Mexico
Prior art keywords
cd40l
methods
fusion polypeptides
fusion protein
antibody
Prior art date
Application number
MX2018013762A
Other languages
English (en)
Inventor
Baca Manuel
Drabic Stacey
Emtage Peter
Herbst Ronald
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2018013762A publication Critical patent/MX2018013762A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Abstract

En la presente se proporciona una proteína de fusión CD40L-Fc y métodos para usar la proteína de fusión en el tratamiento del cáncer que comprenden administrar la proteína de fusión CD40L-Fc o la proteína de fusión CD40L-Fc combinada con uno o más inhibidores de puntos de control inmunitario (por ejemplo, un anticuerpo anti-CTLA4 o anticuerpo anti-PD-L1).
MX2018013762A 2016-05-13 2017-05-12 Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso. MX2018013762A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662336129P 2016-05-13 2016-05-13
PCT/US2017/032352 WO2017197231A1 (en) 2016-05-13 2017-05-12 Cd40l-fc fusion polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2018013762A true MX2018013762A (es) 2019-03-28

Family

ID=60267851

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013762A MX2018013762A (es) 2016-05-13 2017-05-12 Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso.

Country Status (18)

Country Link
US (1) US10975155B2 (es)
EP (1) EP3455263A4 (es)
JP (1) JP2019523636A (es)
KR (1) KR20190004319A (es)
CN (1) CN109153729A (es)
AR (1) AR108468A1 (es)
AU (1) AU2017264944A1 (es)
BR (1) BR112018072953A2 (es)
CA (1) CA3022636A1 (es)
CL (1) CL2018003141A1 (es)
CO (1) CO2018013104A2 (es)
IL (1) IL262727A (es)
MA (1) MA44993A (es)
MX (1) MX2018013762A (es)
RU (1) RU2018138703A (es)
SG (1) SG11201809374VA (es)
TW (1) TW201741337A (es)
WO (1) WO2017197231A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2310509T3 (pl) * 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
BR112016005303A2 (pt) 2013-09-11 2017-09-12 Medimmune Ltd anticorpos anti-b7-h1 para tratamento de tumores
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
LT3565579T (lt) 2017-01-05 2023-09-11 Kahr Medical Ltd. Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai
CA3047708A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirpalpha-41bbl fusion protein and methods of use thereof
US20220135649A1 (en) * 2019-02-06 2022-05-05 The Regents Of The University Of California Dominant negative cd40l polypeptides
JP2022540187A (ja) * 2019-07-08 2022-09-14 プロジェン・カンパニー・リミテッド 新規融合タンパク質及びその用途
AU2021210773A1 (en) * 2020-01-23 2022-08-25 Genexine, Inc. Fusion protein comprising pd-l1 protein and use thereof
WO2023088876A1 (en) * 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100453314B1 (ko) * 1995-06-07 2004-12-17 임뮤넥스 코포레이션 Cd40l 돌연변이 단백질
CZ297300B6 (cs) * 1996-07-08 2006-11-15 The Trustees Of Columbia University In The City Of New York Lécivo, které obsahuje protilátku inhibující vazbu ligandu CD40 na CD40 a je urcené k lécení nemocízávislých na bunkách hladkého svalstva
US6774225B2 (en) 1999-04-15 2004-08-10 Hong Kong University Of Science & Technology Antigenized antibody vaccine for foot-and-mouth disease
CN1461344A (zh) * 2000-07-25 2003-12-10 免疫医疗公司 多价靶结合蛋白
US7238499B2 (en) * 2001-12-21 2007-07-03 Immunex Corporation Trimeric macrophage scavenger receptor fusion proteins and encoding nucleic acids
PT2444424T (pt) * 2005-05-20 2018-11-09 Ablynx Nv Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
PL2310509T3 (pl) 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
MA41460A (fr) * 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
EP3292143B1 (en) * 2015-05-04 2019-08-21 Apogenix AG Single-chain cd40-receptor agonist proteins

Also Published As

Publication number Publication date
WO2017197231A1 (en) 2017-11-16
MA44993A (fr) 2019-03-20
KR20190004319A (ko) 2019-01-11
JP2019523636A (ja) 2019-08-29
IL262727A (en) 2018-12-31
AU2017264944A1 (en) 2018-12-20
CO2018013104A2 (es) 2018-12-14
EP3455263A1 (en) 2019-03-20
US10975155B2 (en) 2021-04-13
AR108468A1 (es) 2018-08-22
RU2018138703A (ru) 2020-06-15
TW201741337A (zh) 2017-12-01
CA3022636A1 (en) 2017-11-16
CN109153729A (zh) 2019-01-04
BR112018072953A2 (pt) 2019-02-19
CL2018003141A1 (es) 2018-12-28
EP3455263A4 (en) 2020-01-01
US20170327588A1 (en) 2017-11-16
SG11201809374VA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
MX2018013762A (es) Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso.
MX2020013169A (es) Conjugados de camptotecina.
IL278920A (en) ENTPD2 antibodies, combination therapies, and methods of using antibodies and combination therapies
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
MX2019003780A (es) Uso de la combinación de anticuerpo anti-pd-1 e inhibidor de vegfr en la preparación de medicamentos para el tratamiento de cánceres.
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
NZ750974A (en) Antibody and checkpoint inhibitor combination therapy
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
PH12019501146A1 (en) Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2018008995A (es) Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer.
SG11201811724TA (en) Translation device and translation method
MY191944A (en) Binding proteins and methods of use thereof
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
CA3060516A1 (en) Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
MX2019011624A (es) Metodos y composiciones para la reduccion de la inmunogenicidad.
SG10201809701TA (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
MX2018006152A (es) Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
BR112016029935A2 (pt) ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?